

30 January 2013 EMA/199793/2011

EU Clinical Trials Register – Frequently Asked Questions

Questions and answers relating to practical and technical aspects of the EU Clinical Trials Register

IMPORTANT: Users should continue to refer to the <u>How to Search EU Clinical Trials Register guide</u> (under 'Click here for more information' on the EU CTR Search page) for detailed guidance on using the search functionality.

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom **Telephone** +44 (0)20 7418 8400 **Facsimile** +44 (0)20 **E-mail** info@ema.europa.eu **Website** www.ema.europa.eu



An agency of the European Union

© European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged.

Q.1. What is the EU Clinical Trials Register? What does it do?

A. The EU Clinical Trials Register website is part of EudraPharm. EudraPharm is the Community database of authorised medicinal products and with the launch of the new website will also provide information on clinical trials of medicinal products with or without a marketing authorisation. The website provides public access to information extracted from the EU clinical trial database <u>EudraCT</u>.

It provides the public with information on clinical trials which have been authorised in the EEA and also those which are part of a PIP (Paediatric Investigation Plan). It gives users the ability to search for information on any paediatric clinical trial and any Phase II-IV adult clinical trial recorded in EudraCT. The paediatric clinical trials included are those with investigator sites in the EEA and also those which form part of a PIP where the investigator sites are all outside the EEA. The adult trials are those with investigator sites in the EEA or listed in PIP

Q.2. Why has www.clinicaltrialsregister.eu been launched?

A. The EU Clinical Trials Register website provides the public with information held in the EU clinical trial database, EudraCT. EudraCT is used by national medicine regulatory authorities to support supervision of clinical trials and was established as a confidential database, in accordance with article 11 of Directive 2001/20/EC. EU pharmaceutical legislation requires the European Medicines Agency (EMA), which maintains the EudraCT database on behalf of EU member states to provide information held in EudraCT to the public. This is described in article 57 of Regulation (EC) No 726/2004 and article 41 of the Paediatric Regulation (EC) No 1901/2006. Together, they establish that data on clinical trials conducted in adults and in paediatric populations should be made public. The EU Clinical Trials Register website puts these requirements into practice.

Q.3. What information can I find in the EU Clinical Trials Register?

A. The EU Clinical Trials Register website contains:

- the description of **a phase II-IV adult clinical trial** where the investigator sites are in European Union member states and the European Economic Area;
- the description of **any paediatric clinical trial** with investigator sites in the European Union and any trials which form part of a paediatric investigation plan (PIP) including those where the investigator sites are outside the European Union.

The EU Clinical Trials Register website **does not**:

- provide information on the results of clinical trials;
- provide information on non-interventional clinical trials of medicines (observational studies on authorised medicines);*
- for the period May 2004-March 2011 provide information on clinical trials where investigator sites are all outside of the European Union and the European Economic Area. (However, information on clinical trials which are part of an agreed paediatric investigation plan (PIP) and were conducted outside the European Union

and the European Economic Area will be published retroactively on the website by March 2012.);

- provide access to the **authorisation document** from the national medicine regulatory authority or the **opinion document** from the relevant ethics committee;
- provide information on clinical trials for surgical procedures, medical devices or psychotherapeutic procedures;
- manage the process for joining any clinical trial published on the website;

Or

• provide navigation and web content in languages other than **English**.

*Information on non-interventional post authorisation safety studies can be found on the electronic ENCePP register of studies which provides a publicly accessible resource for the registration of pharmacoepidemiological and pharmacovigilance studies.

http://www.encepp.eu/encepp/studiesDatabase.jsp

Q.4. What information is available now?

A. At the moment information on the design of each clinical trial, its sponsor, the investigational medicinal products and therapeutic areas involved and its trial status (authorised, ongoing, complete, etc.) is being made available. Users can search all data available using free text search and filters for member state, age group and gender of trial subjects and phase of trial.

- Clinical trials in the register are those which have been authorised by the national medicine regulatory authority and have a positive opinion of the ethics committee for clinical trials in the Member State where they have been run. In addition, clinical trials including the paediatric population that have received a negative ethics committee opinion are also being made public.
- Phase I clinical trials in adults are not being made public unless they form part of an agreed Paediatric Investigation Plan (PIP). These criteria are those established by the guidelines published by the European Commission.
- From the point at which the first clinical trial goes live on the website all future clinical trials recorded in EudraCT that meet these criteria will be made public.
- In addition the EudraCT database contains clinical trials eligible for publication that have been recorded since EudraCT was established in May 2004, so-called historical data. The Clinical trials already entered in EudraCT that meet the publication criteria are being made public from 22 March 2011.

The EMA is working to improve the functionality of the search tools to refine their ability to find trials relating to particular therapeutic areas, diseases, medicinal products and other criteria users will find helpful. In this respect the Agency's development team maintains close interactions with stakeholders including representatives of patients and consumer groups, healthcare providers, clinical trial sponsors and the national competent authorities of the EU.

Q.5. How do I find the EU Clinical Trials Register?

A. The EU Clinical Trials Register is part of EudraPharm and can be accessed from the EudraPharm homepage

The homepage of EU Clinical Trial Register is: <u>www.clinicaltrialsregister.eu/</u>

Q.6. Who provides the information?

A. The information on clinical trials conducted in the EU Member States is provided, in electronic format, to the national medicine regulatory authorities by the trial sponsors as part of the sponsor's application for authorisation to conduct a trial. It is entered into the database by the national medicine regulatory authority which adds the authorisation and the ethics committee opinion, and later completes the end-of-trial information.

The information on third-country clinical trials is supplied by Paediatric-Investigation-Plan (PIP) addressees who post the information directly onto the system via the EMA.

Q.7. What are the plans for the future?

A. Plans for the future include the publication of summaries of results. This functionality will be included in EudraCT V 9.0 and its structure will be based on a Guideline to be published by the European Commission (EC).

The draft version of that guideline was published for consultation from May to September 2010.

The guideline may be viewed here:

http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC50 0003642.pdf

The EMA is closely working with the National Institute of Health (US) which manages the http://clinicaltrials.gov/ registry, and with HL7's CTRR (Health Level 7 - Clinical Trial Registration and Results) project on the harmonisation of the data sets that should be submitted by the sponsor to clinical trial registers. The Agency is also working with the WHO in the context of the International Clinical Trials Registry Platform (ICTRP) http://www.who.int/ictrp/en/.

Q.8. Data displayed for some clinical trials are incomplete. What will be done to improve data quality?

A. National medicine regulatory authorities and the Agency are working to develop, where possible, a more complete data set for historical trials (May 2004-March 2011 data entered in the EudraCT database). They are also working to improve the quality of the new records through enhanced automated checking and quality control from the launch of EudraCT V 8.0 onwards and through the increased use of standardised data.

Now that the EU Clinical Trials Register website has been launched these issues are the key priority.

The keys to data quality are:

• the completion of all relevant fields

- the entry of data in a timely manner
- the use of controlled term lists rather than free text, wherever possible.

With the launch of version 8.0 of EudraCT in March 2011 a much more comprehensive set of validation rules are being put in place. These ensure greater data completeness and consistency.

All active substances newly entered into EudraCT must be consistent with the controlled term lists following further improvements in 2012

The national medicine regulatory authorities and the Agency are working to ensure timely entry of information. This will apply to the loading of the initial data supplied by the sponsor, followed by the entry by national medicine regulatory authorities of their authorisation, the ethics committee opinion and later the end of trial information. In particular the availability of the new data warehouse starting with the new release of EudraCT that has just taken place enables the authorities to produce regular reports on data completeness and to ensure any gaps are promptly filled. In addition links are being established so that those national medicine regulatory authorities that also operate their own databases can load data directly from those systems.

Data quality and historical information:

Information on clinical trials entered into the database between 1 May 2004 and the release of the latest version of EudraCT (Version 8.0) is what is referred to here as historical data. It may be incomplete or contain inconsistencies. For instance, the end-date of a trial may not have been entered, so the trial may appear to have a trial status of 'Ongoing' when in fact it has been completed. Member states implemented the Directive and started using EudraCT at different times between 2004 and 2006 and the links with the ethics committees have needed to be established. The validation rules applying to the data have been considerably upgraded and the EMA is working with national medicine regulatory authorities to ensure key data on the status of existing trials is completed.

Q.9. Where do I get more information for a specific trial?

A. In order to obtain additional information on a particular trial of interest users should address their request directly to the sponsor of the trial. A <u>sponsor contact information list</u> is accessible <u>here</u> and is also provided on the <u>Clinical Trial Sponsors page</u> of the EU Clinical Trials Register website to facilitate communication between the public and stakeholders.

Please note that the sponsors list is not exhaustive.. The Agency will add contact information provided by any sponsor providing it. Contact information should be sent to <u>euctr@ema.europa.eu</u>.

The requirement to provide public contact information is a new feature of EudraCT version 8.0 and was not previously requested. As a consequence this information is not available for the historical clinical trials as it was not a requirement in the past.

If you cannot find the sponsor contact details information in the clinical trial record or the list provided, you will need to look for information on the Internet, from your patient or professional association, your healthcare provider or other sources.

Q.10. What do I have to do if I want to join a trial?

A. If you believe that there is a trial that could be of interest to you, it is recommended that you discuss this with your healthcare professional, where possible.

To contact the sponsor for further information, please refer to the contact point in the clinical trial record or the <u>Clinical Trials Sponsors</u> page of www.clinicaltrialsregister.eu.

Patients should not interpret the information provided in the register as a recommendation to use the medicine or to participate in the trial. Patients should consult their treating physician or the trial investigator to discuss appropriate treatment options.

Q.11. The clinical trial I am interested in is not in the EU Clinical Trials Register website? Why is that?

A. There can be different explanations for this including (the most likely):

- the clinical trial does not have a site in the EEA and it is not part of a Paediatric Investigation Plan (PIP);
- the trial has started before the implementation of the Clinical Trial Directive 2001/20/EC in 2004;
- the clinical trial is part of historical data not yet publicly available;
- The trial does not correspond to the clinical trials being made public e.g. it is a Phase I clinical trial conducted in adults, or it is not a clinical trial of medicines but of a medical device or other therapeutic procedure.

Q.12. Why do some fields in the detailed clinical trial application view have 'Information not present in EudraCT'?

- A: Potential reasons for this are:
- It is a new field for which data is only being collected from 10 March 2011 onwards older trial records do not have this information.
- Historical records that have less information, due to less stringent requirements for data completion or absence of some fields in earlier versions of EudraCT.
- The information has not been entered by the sponsor.
- Some fields may not be relevant for some clinical trial designs or the medicines being tested.

Q.13. Can I use the Back/Forward button in my Internet Explorer when I access EU Clinical Trials Register?

A: Back/Forward browser buttons are fully supported and can be used for navigation, in conjunction with the navigation provided by the menu bar.

Q.14. Can I copy the URL of the summary or detailed view of a record?

A: Following recent enhancements to the usability of the application, you can now copy or bookmark URLs since they are now displayed in a logical and user friendly format.

Q.15. What is RSS?

A: RSS stands for Really Simple Syndication. This allows you to receive updates to content from websites which provide a web feed (also called an RSS feed). To do this you subscribe to the web feed. The web feed is then gathered in your browser's RSS reader for you to view at your convenience. Different browsers support web feeds in different ways; search your browser's help for information on its particular implementation.

An important new feature of the EU Clinical Trials Register is the provision of customised RSS feeds for any search you might make regularly on the website.

For example, if you are interested in clinical trials concerning 'Bowel Cancer', you can tailor your search within EU Clinical Trials Register search page then simply subscribe to the RSS feed for your search by clicking the RSS link: Subscribe to this Search

Once subscribed, you'll be able to see when your search returns additional results via your RSS reader. Note that this feature is not available in Internet Explorer 6.

Q.16. Can I search for clinical trials based on gender?

A: After feedback, post-launch, this feature is now available within the EU Clinical Trials Register to allow interested parties to find clinical trials focussed specifically upon one gender. Use the '**Select Gender:'** drop-down on the EU Clinical Trials Register search page.

Q.17. Why was the EU Clinical Trials Register website launched later than expected?

A. When the EU clinical trial database, EudraCT was set up on 1 May 2004, the legal framework established it as a confidential database. This confidentiality was partially lifted by Regulation (EC) No 726/2004 and Regulation (EC) No 1901/2006. Both regulations needed to have implementing guidance prepared and published and these were published by the European Commission in July 2008 and February 2009. Originally the website was scheduled to be released at the end of 2009, but the challenges of converting the database to its current structure to support this and future developments, and additional difficulties encountered in data migration and testing of the software meant that the release was delayed until March 2011.

Q.18. Q: When I select country UK with status 'Ongoing', why does the result contain Clincal Trials with participating country GB and status 'Completed'?

A: Such a search returns a list of results for clinical trials for which the values 'GB' and 'Ongoing' are present. It should be noted that this does not mean that the status 'Ongoing' is necessarily associated with the country GB. Rather, it is associated with the clinical trial itself which may have a multiple trial statuses associated with each of the participating countries.

Q.19. Why is the sum result of a search for UK Phase II Ongoing trials commenced in 2011 and that of UK Phase II Completed trials commenced in 2011 not the same as the sum result of UK Phase II Ongoing and Completed trials commenced in 2011?

A: Trial status of 'Completed' and of 'Ongoing' may be present in a single Clinical Trial, since a trial will frequently take place in multiple countries. For example, a Clinical Trial taking place in

the UK and also in France might, at some point in time, have a trial status of 'Completed' in France and 'Ongoing' in the UK.

Such Clinical Trials therefore belong to the intersection between the two other sets of search results, since they fulfil both search criteria (i.e. **UK Phase II Ongoing trials commenced in 2011** and **UK Phase II Completed trials commenced in 2011**) as the below Venn diagram illustrates:



Simply adding together the numbers of set 1 (UK Phase II 'Ongoing' 2011 (313)) and set 2 (UK Phase II 'Completed' 2011 (48)) would result in double counting 30 Clinical Trials in the intersection, so these must be subtracted to reach an accurate total.

Q.20. What should I do if my question isn't answered here?

A: If your question regarding the EU Clinical Trials Register is not answered here, or in the <u>How</u> to <u>Search EU Clinical Trials Register guide</u>, please send your question to <u>euctr@ema.europa.eu</u> for a response. Frequently asked questions will be added to this document, as deemed appropriate.